Prognostic Applications of Gene Expression Signatures in Breast Cancer

被引:15
作者
Normanno, Nicola [1 ,2 ]
De Luca, Antonella [1 ]
Carotenuto, Pietro [2 ]
Lamura, Luana [1 ]
Oliva, Ilaria [1 ]
D'Alessio, Amelia [1 ]
机构
[1] INT Fondaz Pascale, Cell Biol & Biotherapy Unit, IT-80131 Naples, Italy
[2] CROM, Pharmacogen Lab, Mercogliano, Italy
关键词
Breast cancer; Gene expression profiling; Prognosis; PREOPERATIVE CHEMOTHERAPY; PHARMACOGENOMIC PREDICTOR; MOLECULAR SUBTYPES; GENOMIC GRADE; RECURRENCE; TAMOXIFEN; INDEX; CYCLOPHOSPHAMIDE; FLUOROURACIL; DOXORUBICIN;
D O I
10.1159/000258489
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Analysis by DNA microarrays has led to the identification of molecular subtypes of breast carcinomas that show a distinct expression profile. Several studies have demonstrated that this 'intrinsic subtype' classification has a strong prognostic value. In addition, gene expression profiling techniques have been used to identify gene signatures that could be associated with the outcome of breast cancer patients. Several different genomic tests have been shown to better define the prognosis of early-stage breast cancer patients as compared with conventional clinical and pathological characteristics of the tumors, and some assays are already commercially available. However, it must be emphasized that the prognostic power of these genetic classifiers has not been confirmed yet in prospective trials. Genetic signatures that might predict the activity of specific chemotherapy agents have also been developed by using gene expression profiling techniques. The same approach has been used to identify gene signatures associated with the activation of oncogenic pathways that might represent targets for molecular therapy of breast cancer. By using these approaches, gene expression techniques might significantly improve our ability to predict the risk of recurrence and to tailor the treatment for each individual breast cancer patient. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:2 / 8
页数:7
相关论文
共 35 条
  • [1] RETRACTED: Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer (Retracted Article)
    Acharya, Chaitanya R.
    Hsu, David S.
    Anders, Carey K.
    Anguiano, Ariel
    Salter, Kelly H.
    Walters, Kelli S.
    Redman, Richard C.
    Tuchman, Sascha A.
    Moylan, Cynthia A.
    Mukherjee, Sayan
    Barry, William T.
    Dressman, Holly K.
    Ginsburg, Geoffrey S.
    Marcom, Kelly P.
    Garman, Katherine S.
    Lyman, Gary H.
    Nevins, Joseph R.
    Potti, Anil
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (13): : 1574 - 1587
  • [2] Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer
    Ayers, M
    Symmans, WF
    Stec, J
    Damokosh, AI
    Clark, E
    Hess, K
    Lecocke, M
    Metivier, J
    Booser, D
    Ibrahim, N
    Valero, V
    Royce, M
    Arun, B
    Whitman, G
    Ross, J
    Sneige, N
    Hortobagyi, GN
    Pusztai, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) : 2284 - 2293
  • [3] Does triple-negative phenotype accurately identify basal-like turnour?: An immunohistochemical analysis based on 143 'triple-negative' breast cancers
    Bidard, F.-C.
    Conforti, R.
    Boulet, T.
    Michiels, S.
    Delaloge, S.
    Andre, F.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (07) : 1285 - 1286
  • [4] Oncogenic pathway signatures in human cancers as a guide to targeted therapies
    Bild, AH
    Yao, G
    Chang, JT
    Wang, QL
    Potti, A
    Chasse, D
    Joshi, MB
    Harpole, D
    Lancaster, JM
    Berchuck, A
    Olson, JA
    Marks, JR
    Dressman, HK
    West, M
    Nevins, JR
    [J]. NATURE, 2006, 439 (7074) : 353 - 357
  • [6] Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
    Buyse, Marc
    Loi, Sherene
    van't Veer, Laura
    Viale, Giuseppe
    Delorenzi, Mauro
    Glas, Annuska M.
    d'Assignies, Mahasti Saghatchian
    Bergh, Jonas
    Lidereau, Rosette
    Ellis, Paul
    Harris, Adrian
    Bogaerts, Jan
    Therasse, Patrick
    Floore, Arno
    Amakrane, Mohamed
    Piette, Fanny
    Rutgers, Emiel
    Sotiriou, Christos
    Cardoso, Fatima
    Piccart, Martine J.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (17): : 1183 - 1192
  • [7] Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival
    Chang, HY
    Nuyten, DSA
    Sneddon, JB
    Hastie, T
    Tibshirani, R
    Sorlie, T
    Dai, HY
    He, YDD
    van't Veer, LJ
    Bartelink, H
    van de Rijn, M
    Brown, PO
    van de Vijver, MJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (10) : 3738 - 3743
  • [8] Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds
    Chang, HY
    Sneddon, JB
    Alizadeh, AA
    Sood, R
    West, RB
    Montgomery, K
    Chi, JT
    van de Rijn, M
    Botstein, D
    Brown, PO
    [J]. PLOS BIOLOGY, 2004, 2 (02) : 206 - 214
  • [9] Triple-negative breast cancer: Clinical features and patterns of recurrence
    Dent, Rebecca
    Trudeau, Maureen
    Pritchard, Kathleen I.
    Hanna, Wedad M.
    Kahn, Harriet K.
    Sawka, Carol A.
    Lickley, Lavina A.
    Rawlinson, Ellen
    Sun, Ping
    Narod, Steven A.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4429 - 4434
  • [10] Concordance among gene-expression-based predictors for breast cancer
    Fan, Cheng
    Oh, Daniel S.
    Wessels, Lodewyk
    Weigelt, Britta
    Nuyten, Dimitry S. A.
    Nobel, Andrew B.
    van't Veer, Laura J.
    Perou, Charles M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (06) : 560 - 569